SKYCLARYS
Drug
Biogen, Inc.
Total Payments
$4.5M
Transactions
2,607
Doctors
1,758
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.5M | 2,607 | 1,758 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $3.4M | 4 | 74.9% |
| Unspecified | $863,076 | 11 | 19.2% |
| Consulting Fee | $110,615 | 44 | 2.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $85,853 | 31 | 1.9% |
| Food and Beverage | $56,285 | 2,487 | 1.3% |
| Grant | $6,500 | 3 | 0.1% |
| Travel and Lodging | $2,351 | 24 | 0.1% |
| Education | $226.50 | 3 | 0.0% |
Payments by Type
General
$3.6M
2,596 transactions
Research
$863,076
11 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of Omaveloxolone in Children With Friedreich's Ataxia (BOLD) | Biogen, Inc. | $392,639 | 0 |
| RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe | Biogen, Inc. | $244,627 | 0 |
| An Open-Label, Single Dose Study to Assess the Breast Milk and Plasma Pharmacokinetics of Omaveloxolone (BIIB141) in Healthy Lactating Women | Biogen, Inc. | $92,154 | 0 |
| A TQTc Study for Omaveloxolone | Biogen, Inc. | $76,523 | 0 |
| An Open-label DDI Study of Omaveloxolone in Healthy Subjects | Biogen, Inc. | $57,134 | 0 |
Top Doctors Receiving Payments for SKYCLARYS — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Neurology with Special Qualifications in Child Neurology | Seattle, WA | $1,713 | 1 |
| , M.D., M.M.S | Neurology with Special Qualifications in Child Neurology | Saint Paul, MN | $1,563 | 1 |
| , MD | Neurology | Boston, MA | $1,541 | 1 |
| , MD | Neurology | Dallas, TX | $1,500 | 1 |
| , M.D | Neurology | New York, NY | $1,226 | 1 |
| , PA-C | Physician Assistant | Georgetown, TX | $675.00 | 1 |
| , M.D | Physical Medicine & Rehabilitation | Sacramento, CA | $149.00 | 2 |
| , M.D | Neurology | Lawrence, MA | $147.20 | 14 |
| , NP-C | Family | Baton Rouge, LA | $143.83 | 7 |
| , M.D | Neurology | Attleboro, MA | $143.06 | 6 |
| , M.D | Neurology | Mansfield, TX | $138.30 | 6 |
| , NP-C | Acute Care | Fort Worth, TX | $138.30 | 6 |
| , M.D | Family Medicine | Charleston, SC | $137.58 | 5 |
| , DNP, APRN, AGNP-C | Gerontology | New York, NY | $132.72 | 2 |
| , D.O | Neurology | Dallas, TX | $129.13 | 6 |
| , MD | Neurology | Cedar Rapids, IA | $128.85 | 6 |
| , MD | Pediatrics | Roswell, GA | $126.71 | 5 |
| , MD | Neuromuscular Medicine | Tustin, CA | $125.00 | 1 |
| , CNP | Family | Attleboro, MA | $122.90 | 5 |
| , M.D | Neurology | Attleboro, MA | $122.90 | 5 |
| , M.D | Internal Medicine | Bedford, TX | $122.09 | 6 |
| , M.D | Neurology | Killeen, TX | $120.30 | 2 |
| Cattien Nguyen | Family | Frisco, TX | $119.33 | 5 |
| , M.D | Neurology | Cheshire, CT | $115.32 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Cheshire, CT | $115.32 | 1 |
Ad
Manufacturing Companies
- Biogen, Inc. $4.5M
Product Information
- Type Drug
- Total Payments $4.5M
- Total Doctors 1,758
- Transactions 2,607
About SKYCLARYS
SKYCLARYS is a drug associated with $4.5M in payments to 1,758 healthcare providers, recorded across 2,607 transactions in the CMS Open Payments database. The primary manufacturer is Biogen, Inc..
Payment data is available from 2024 to 2024. In 2024, $4.5M was paid across 2,607 transactions to 1,758 doctors.
The most common payment nature for SKYCLARYS is "Royalty or License" ($3.4M, 74.9% of total).
SKYCLARYS is associated with 5 research studies, including "A Study of Omaveloxolone in Children With Friedreich's Ataxia (BOLD)" ($392,639).